Intravenous administration of mitochondria for treating experimental Parkinson's disease.

Citation data:

Mitochondrion, ISSN: 1872-8278, Vol: 34, Page: 91-100

Publication Year:
Usage 64
Abstract Views 57
Link-outs 7
Mentions 94
Comments 92
Blog Mentions 2
Social Media 250
Shares, Likes & Comments 157
Tweets 93
Citations 1
Citation Indexes 1
Reddit 196
Shi, Xianxun; Zhao, Ming; Fu, Chen; Fu, Ailing
Elsevier BV
Biochemistry, Genetics and Molecular Biology
Most Recent Tweet View All Tweets
Most Recent Blog Mention
article description
Mitochondrial dysfunction is associated with a large number of human diseases, including neurological and muscular degeneration, cardiovascular disorders, obesity, diabetes, aging and rare mitochondrial diseases. Replacement of dysfunctional mitochondria with functional exogenous mitochondria is proposed as a general principle to treat these diseases. Here we found that mitochondria isolated from human hepatoma cell could naturally enter human neuroblastoma SH-SY5Y cell line, and when the mitochondria were intravenously injected into mice, all of the mice were survived and no obvious abnormality appeared. The results of in vivo distribution suggested that the exogenous mitochondria distributed in various tissues including brain, liver, kidney, muscle and heart, which would benefit for multi-systemically mitochondrial diseases. In normal mice, mitochondrial supplement improved their endurance by increase of energy production in forced swimming test; and in experimental Parkinson's disease (PD) model mice induced by respiratory chain inhibitor MPTP, mitochondrial replacement prevented experimental PD progress through increasing the activity of electron transport chain, decreasing reactive oxygen species level, and preventing cell apoptosis and necrosis. Since effective drugs remain elusive to date for mitochondrial diseases, the strategy of mitochondrial replacement would provide an essential and innovative approach as mitochondrial therapy.